Nippon India Pharma Fund (Direct)
Nippon India Mutual Fund · benchmark Nifty 500 TRI · 13.8 years old · AMFI code 118759
C (bottom 30%), score 34.2 out of 100. Describes the past, not a forecast.
Returns against the index
| Period | Fund | Index (TRI) | Difference | Rank in category |
|---|---|---|---|---|
| 6 months | 9.3% | 2.5% | +6.8% | 15 / 17 |
| 1 year | 10.9% | -1.0% | +11.9% | 12 / 16 |
| 3 years (a year) | 19.0% | 12.0% | +7.0% | 8 / 11 |
| 5 years (a year) | 14.6% | 9.7% | +4.9% | 7 / 7 |
Growth option, point to point to 5 Nov 2026; periods over a year are annualised (CAGR). Index returns use the total-return index, which includes dividends.
Risk
Portfolio
Top 10 holdings, September 2026 portfolio.
Common questions
What is the NAV of Nippon India Pharma Fund (Direct plan)?
₹640.95 on 5 Nov 2026 (Growth option).
What is the expense ratio of Nippon India Pharma Fund (Direct)?
0.99% a year; the Regular plan's is 1.83%.
What return has Nippon India Pharma Fund given over 3 years?
19.0% a year (Direct plan) over the 3 years to 5 Nov 2026, against 12.0% for the Nifty 500 total-return index.
What does Nippon India Pharma Fund invest in?
Its largest holdings are Sun Pharmaceutical Industries Limited, Divi's Laboratories Limited, Lupin Limited, with 36 stocks in all (September 2026 portfolio).
How is Nippon India Pharma Fund rated?
C: 9 of 11 Direct plans in Thematic: Pharma & Healthcare, on its track record. This describes the past and is not a recommendation.
Data as of 5 Nov 2026: NAVs from AMFI, index data from NSE Indices, portfolios from Nippon India Mutual Fund's monthly disclosure. Updated every weekday. Read the scheme documents before investing.